Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 1 mg - capsule, hard - excipient ingredients: hypromellose; gelatin; ethanol absolute; lactose; titanium dioxide; purified water; magnesium stearate; methyl chloride; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 0.5 mg - capsule, hard - excipient ingredients: gelatin; magnesium stearate; titanium dioxide; methyl chloride; iron oxide yellow; hypromellose; purified water; lactose; croscarmellose sodium; ethanol absolute; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 5 mg - capsule, hard - excipient ingredients: hypromellose; titanium dioxide; ethanol absolute; gelatin; purified water; magnesium stearate; lactose; croscarmellose sodium; methyl chloride; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 0.5 mg - capsule, hard - excipient ingredients: gelatin; croscarmellose sodium; titanium dioxide; methyl chloride; iron oxide yellow; ethanol absolute; hypromellose; lactose; purified water; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; iron oxide red; lactose; methyl chloride; titanium dioxide; hypromellose; magnesium stearate; ethanol absolute; purified water; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus, quantity: 1 mg - capsule, hard - excipient ingredients: methyl chloride; gelatin; magnesium stearate; purified water; ethanol absolute; hypromellose; titanium dioxide; croscarmellose sodium; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: purified water; lactose monohydrate; maize starch; patent blue v; magnesium stearate; titanium dioxide; erythrosine; gelatin; colloidal anhydrous silica; sodium lauryl sulfate - fluconazole apotex (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.